» Articles » PMID: 34155314

Synthesis of [At]4-astato-L-phenylalanine by Dihydroxyboryl-astatine Substitution Reaction in Aqueous Solution

Overview
Journal Sci Rep
Specialty Science
Date 2021 Jun 22
PMID 34155314
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Astatine-211 (At)-labeled phenylalanine is expected to be a promising agent for targeted alpha-particle therapy for the treatment of patients with glioma. The existing reactions to prepare the labeled compound usually require organic solvents and metals that are toxic and hazardous to the environment. In this study, we developed a novel method wherein astatination was realized via the substitution of At for a dihydroxyboryl group coupled to phenylalanine. [At]4-astato-L-phenylalanine was obtained as the carrier-free product in aqueous medium in high radiochemical yields (98.1 ± 1.9%, n = 5). The crude reaction mixture was purified by solid-phase extraction, and the radiochemical purity of the product was 99.3 ± 0.7% (n = 5). The high yield and purity were attributed to the formation of [At]AtI and AtI as the reactive intermediates in the astatination reaction. The reaction did not require any organic solvents or toxic reagents, suggesting that this method is suitable for clinical applications.

Citing Articles

Development of LAT1-Selective Nuclear Medicine Therapeutics Using Astatine-211.

Kaneda-Nakashima K, Shirakami Y, Hisada K, Feng S, Kadonaga Y, Ooe K Int J Mol Sci. 2024; 25(22).

PMID: 39596451 PMC: 11594329. DOI: 10.3390/ijms252212386.


Comparison Length of Linker in Compound for Nuclear Medicine Targeting Fibroblast Activation Protein as Molecular Target.

Hisada K, Kaneda-Nakashima K, Shirakami Y, Kadonaga Y, Saito A, Watabe T Int J Mol Sci. 2024; 25(22).

PMID: 39596363 PMC: 11594969. DOI: 10.3390/ijms252212296.


Astatine-211 radiolabelling chemistry: from basics to advanced biological applications.

Vanermen M, Ligeour M, Oliveira M, Gestin J, Elvas F, Navarro L EJNMMI Radiopharm Chem. 2024; 9(1):69.

PMID: 39365487 PMC: 11452365. DOI: 10.1186/s41181-024-00298-4.


The Different Strategies for the Radiolabeling of [At]-Astatinated Radiopharmaceuticals.

Gao J, Li M, Yin J, Liu M, Wang H, Du J Pharmaceutics. 2024; 16(6).

PMID: 38931860 PMC: 11206656. DOI: 10.3390/pharmaceutics16060738.


Preclinical Evaluation of Biodistribution and Toxicity of [At]PSMA-5 in Mice and Primates for the Targeted Alpha Therapy against Prostate Cancer.

Watabe T, Kaneda-Nakashima K, Kadonaga Y, Ooe K, Sampunta T, Hirose N Int J Mol Sci. 2024; 25(11).

PMID: 38891856 PMC: 11172375. DOI: 10.3390/ijms25115667.


References
1.
Aneheim E, Albertsson P, Back T, Jensen H, Palm S, Lindegren S . Automated astatination of biomolecules--a stepping stone towards multicenter clinical trials. Sci Rep. 2015; 5:12025. PMC: 4500947. DOI: 10.1038/srep12025. View

2.
Watabe T, Kaneda-Nakashima K, Shirakami Y, Liu Y, Ooe K, Teramoto T . Targeted alpha therapy using astatine (At)-labeled phenylalanine: A preclinical study in glioma bearing mice. Oncotarget. 2020; 11(15):1388-1398. PMC: 7170498. DOI: 10.18632/oncotarget.27552. View

3.
Nagatsu K, Minegishi K, Fukada M, Suzuki H, Hasegawa S, Zhang M . Production of (211)At by a vertical beam irradiation method. Appl Radiat Isot. 2014; 94:363-371. DOI: 10.1016/j.apradiso.2014.09.012. View

4.
Pozzi O, Zalutsky M . Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for At labeling at high activities and radiation doses of At α-particles. Nucl Med Biol. 2016; 46:43-49. PMC: 5285439. DOI: 10.1016/j.nucmedbio.2016.11.009. View

5.
Meyer G, Walte A, Sriyapureddy S, Grote M, Krull D, Korkmaz Z . Synthesis and analysis of 2-[211At]-L-phenylalanine and 4-[211At]-L-phenylalanine and their uptake in human glioma cell cultures in-vitro. Appl Radiat Isot. 2010; 68(6):1060-5. DOI: 10.1016/j.apradiso.2009.12.043. View